Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension

被引：9

作者：

Davey, Ryan ^{[1
]}

Benza, Raymond L. ^{[2
]}

Murali, Srinivas ^{[2
]}

Raina, Amresh ^{[2
]}

机构：

[1] Western Univ, Div Cardiol, London, ON, Canada

[2] Allegheny Gen Hosp, Cardiovasc Inst, Pittsburgh, PA 15212 USA

来源：

PULMONARY CIRCULATION | 2017年 / 7卷 / 02期

关键词：

hemodynamics; pulmonary arterial hypertension; rioicguat; transition; ARTERIAL-HYPERTENSION; SILDENAFIL; MANAGEMENT;

D O I：

10.1177/2045893217708566

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Riociguat is a soluble guanylate cyclase stimulator approved for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. We studied the clinical and hemodynamics effects of transitioning 12 pulmonary hypertension patients from Phosphodiesterase type 5 inhibitor (PDE5i) to riociguat, and demonstrated a significant increase in cardiac index, fall in pulmonary vascular resistance, and improvement in functional class with this switch. Switch from PDE5i to riociguat appeared to be safe and fairly well tolerated in most patients.

引用

页码：539 / 542

页数：4

共 12 条

[11] Pharmacologic Therapy for Pulmonary Arterial Hypertension in Adults CHEST Guideline and Expert Panel Report [J].

Taichman, Darren B. ;

Ornelas, Joe ;

Chung, Lorinda ;

Klinger, James R. ;

Lewis, Sandra ;

Mandel, Jess ;

Palevsky, Harold I. ;

Rich, Stuart ;

Sood, Namita ;

Rosenzweig, Erika B. ;

Trow, Terence K. ;

Yung, Rex ;

Elliott, C. Gregory ;

Badesch, David B. .

CHEST, 2014, 146 (02) :449-475

[12] Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension [J].

Toshner, Mark R. ;

Gopalan, Deepa ;

Suntharalingam, Jay ;

Treacy, Carmen ;

Soon, Elaine ;

Sheares, Karen K. ;

Morrell, Nicholas W. ;

Screaton, Nicholas ;

Pepke-Zaba, Joanna .

JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (06) :610-615

← 1 2 →